XM
PTCT icon

XTX Markets’s PTC Therapeutics PTCT Stock Holding History

XTX Markets’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$221K Buy
+3,620
New +$213K 0.46% 112

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

XTX Markets's PTCT Position: Q4 2020 in Review

XTX Markets opened a new position in PTC Therapeutics (PTCT) in Q4 2020: 3,620 shares worth $221K. The stake represents 0.46% of the portfolio and ranks #112 among its holdings.

215 funds tracked by Wall St. Rank hold PTCT as of Q4 2020.

  • XTX Markets held 3,620 shares of PTC Therapeutics worth $221K as of Q4 2020.
  • PTC Therapeutics was a new XTX Markets position in Q4 2020.
  • PTC Therapeutics made up 0.46% of XTX Markets's portfolio in Q4 2020, its #112 holding.
  • 215 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2020.

Based on XTX Markets's 13F filing for Q4 2020, filed 25 Jan 2021.